Increased inflammatory response in patients with dilated cardiomyopathy is associated with dyslipidemia: Effects of statin therapy

Angiology

Volumn 62, Issue 1, 2011, Pages 55-61

  Iakovis, Panagiotis ^a   Anyfantakis, Zaharias Alexandros ^a   Limas, Constantinos ^a   Kroupis, Christos ^a,b   Degiannis, Dimitrios ^a   Cokkinos, Dennis V ^a,c  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c BIOMEDICAL RESEARCH FOUNDATION   (Greece)

Author keywords

dilated cardiomyopathy; hypercholesterolemia; immunity; inflammation; statins

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 2 RECEPTOR; SIMVASTATIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; HUMAN; INFLAMMATION; LOW FAT DIET; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT; TREATMENT OUTCOME;

CARDIOMYOPATHY, DILATED; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SIMVASTATIN;

EID: 78650209817     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319710384396     Document Type: Article

References (49)

1. Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med. 1994 ; 331 (23). 1564-1575.
2. Devaux B., Scholz D., Hirche A., Klövekorn WP, Schaper J. Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure. Eur Heart J. 1997 ; 18 (3). 470-479.
3. Yang LL, Gros R., Kabir MG, et al. Conditional cardiac overexpression of endothelin-1 induces inflammation and dilated cardiomyopathy in mice. Circulation. 2004 ; 109 (2). 255-261.
4. Munger MA, Johnson B., Amber IJ, Callahan KS, Gilbert EM Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1996 ; 77 (9). 723-727.
5. Aukrust P., Ueland T., Lien E., et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1999 ; 83: 376-382.
6. Smith SC, Allen PM Myosin-induced acute myocarditis is a T cell-mediated disease. J Immunol. 1991 ; 147 (7). 2141-2147.
7. Levine B., Kalman J., Mayer L., Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990 ; 323 (4). 236-241.
8. Torre-Amione G., Kapadia S., Benedict C., Oral H., Young JB, Mann DL Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 1996 ; 27 (5). 1201-1206.
9. Kuhl U., Noutsias M., Seeberg B., Schultheiss HP Immunohistological evidence for a chronic intramyocardial inflammatory process in dilated cardiomyopathy. Heart. 1996 ; 75 (3). 295-300. (Pubitemid 26094969)
10. Holzinger C., Schollhammer A., Imhof M., et al. Phenotypic patterns of mononuclear cells in dilated cardiomyopathy. Circulation. 1995 ; 92 (10). 2876-2885.
11. Limas C. J, Goldenberg IF, Limas C. Soluble interleukin-2 receptor levels in patients with dilated cardiomyopathy. Correlation with disease severity and cardiac autoantibodies. Circulation. 1995 ; 91 (3). 631-634.
12. Limas CJ, Hasikidis C., Iakovou J., Kroupis C., Haidaroglou A., Cokkinos DV Prognostic significance of soluble interleukin-2 receptor levels in patients with dilated cardiomyopathy. Eur J Clin Invest. 2003 ; 33 (6). 443-448.
13. Kell R., Haunstetter A., Dengler TJ, Zugck C., Kübler W., Haass M. Do cytokines enable risk stratification to be improved in NYHA functional class III patients? Comparison with other potential predictors of prognosis. Eur Heart J. 2002 ; 23 (1). 70-78.
14. Chin BS, Blann AD, Gibbs CR, Chung NA, Conway DG, Lip GY Prognostic value of interleukin-6, plasma viscosity, fibrinogen, von Willebrand factor, tissue factor and vascular endothelial growth factor levels in congestive heart failure. Eur J Clin Invest. 2003 ; 33 (11). 941-948.
15. Node K., Fujita M., Kitakaze M., Hori M., Liao JK Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation. 2003 ; 108 (7). 839-843.
16. Gurgun C., Ildizli M., Yavuzgil O., et al. The effects of short term statin treatment on left ventricular function and inflammatory markers in patients with chronic heart failure. Int J Cardiol. 2008 ; 123 (2). 102-107.
17. Mozaffarian D., Nye R., Levy WC Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol. 2004 ; 93 (9). 1124-1129.
18. Domanski M., Coady S., Fleg J., Tian X., Sachdev V. Effect of statin therapy on survival in patients with nonischemic dilated cardiomyopathy (from the Beta-blocker Evaluation of Survival Trial [BEST]). Am J Cardiol. 2007 ; 99 (10). 1448-1450.
19. Schonbeck U., Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation. 2004 ; 109 (21 suppl 1). 1118-1126.
20. Albert MA, Danielson E., Rifai N., Ridker PM ;. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001 ; 286 (1). 64-70.
21. Rosenson RS, Tangney CC, Casey LC Inhibition of proinflammatory cytokine production by pravastatin. Lancet. 1999 ; 353 (9157). 983-984.
22. Holm T., Andreassen AK, Ueland T., et al. Effect of pravastatin on plasma markers of inflammation and peripheral endothelial function in male heart transplant recipients. Am J Cardiol. 2001 ; 87 (6). 815-818 ;, A9.
23. Bellosta S., Via D., Canavesi M., et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol. 1998 ; 18 (11). 1671-1678.
24. Aikawa M., Rabkin E., Sugiyama S., et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation. 2001 ; 103 (2). 276-283.
25. Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley AJ 3rd, Spinale FG Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation. 1998 ; 97 (17). 1708-1715.
26. Spinale FG, Coker ML, Heung LJ, et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation. 2000 ; 102 (16). 1944-1949.
27. Sawada N., Li Y., Liao JK Novel aspects of the roles of Rac1 GTPase in the cardiovascular system. Curr Opin Pharmacol. 2010 ; 10 (2). 116-121.
28. Richardson P., McKenna W., Bristow M., et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation. 1996 ; 93 (5). 841-842.
29. Dickstein K., Cohen-Solal A., Filippatos G., et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur Heart J. 2008 ; 29 (19). 2388-2442.
30. Limas CJ, Iakovis P., Anyfantakis A., Kroupis C., Cokkinos DV Familial clustering of autoimmune diseases in patients with dilated cardiomyopathy. Am J Cardiol. 2004 ; 93 (9). 1189-1191.
31. Lundman P., Eriksson MJ, Silveira A., et al. Relation of hypertriglyceridemia to plasma concentrations of biochemical markers of inflammation and endothelial activation (C-reactive protein, interleukin-6, soluble adhesion molecules, von Willebrand factor, and endothelin-1). Am J Cardiol. 2003 ; 91 (9). 1128-1131.
32. Antonaci S., Jirillo E., Garofalo AR, et al. Cell-mediated immune response in patients with type IIa, type IIb and type IV primary hyperlipoproteinaemia. Cytobios. 1988 ; 54 (218-219). 181-189.
33. Han SN, Leka LS, Lichtenstein AH, Ausman LM, Meydani SN Effect of a therapeutic lifestyle change diet on immune functions of moderately hypercholesterolemic humans. J Lipid Res. 2003 ; 44 (12). 2304-2310.
34. Muldoon MF, Marsland A., Flory JD, et al. Immune system differences in men with hypo- or hypercholesterolemia. Clin Immunol Immunopathol. 1997 ; 84: 145-149.
35. Ludewig B., Jaggi M., Dumrese T., et al. Hypercholesterolemia exacerbates virus-induced immunopathologic liver disease via suppression of antiviral cytotoxic T cell responses. J Immunol. 2001 ; 166 (5). 3369-3376.
36. Garlichs CD, John S., Schmeisser A., et al. Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation. 2001 ; 104 (20). 2395-2400.
37. Zhou X., Paulsson G., Stemme S., Hansson GK Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J Clin Invest. 1998 ; 101 (8). 1717-1725.
38. Fehr T., Kahlert C., Fierz W., et al. Statin-induced immunomodulatory effects on human T cells in vivo. Atherosclerosis. 2004 ; 175 (1). 83-90.
39. Kwak B., Mulhaupt F., Myit S., Mach F. Statins as a newly recognized type of immunomodulator. Nat Med. 2000 ; 6 (12). 1399-1402.
40. Mach F. Immunosuppressive effects of statins. Atheroscler Suppl. 2002 ; 3 (1). 17-20.
41. Mach F. Statins as immunomodulatory agents. Circulation. 2004 ; 109 (21 suppl 1). 1115-1117.
42. Kostakou P., Kolovou G., Anagnostopoulou K., et al. Efficacy of simvastatin or ezetimibe on tissue factor, von Willebrand's factor and C-reactive protein in patients with hypercholesterolaemia. Arch Cardiovasc Dis. 2010 ; 103: 26-32.
43. Blum A., Lang N., Peleg A., et al. Effects of oral soy protein on markers of inflammation in postmenopausal women with mild hypercholesterolemia. Am Heart J. 2003 ; 145 (2). e7.
44. Bielecka-Dabrowa A., Goch JH, Mikhailidis DP, Rysz J., Maciejewski M., Banach M. The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy. Med Sci Monit. 2009 ; 15 (12). MS12 - MS23.
45. Liu M., Wang F., Wang Y., Jin R. Atorvastatin improves endothelial function and cardiac performance in patients with dilated cardiomyopathy: the role of inflammation. Cardiovasc Drugs Ther. 2009 ; 23 (5). 369-376.
46. Colquhoun DM, Jackson R., Walters M., et al. Effects of simvastatin on blood lipids, vitamin E, coenzyme Q10 levels and left ventricular function in humans. Eur J Clin Invest. 2005 ; 35 (4). 251-258.
47. Mason JW, O'Connell JB, Herskowitz A., et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med. 1995 ; 333 (5). 269-275.
48. Gullestad L., Aass H., Fjeld JG, et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation. 2001 ; 103 (2). 220-225. (Pubitemid 32095406)
49. McNamara DM, Holubkov R., Starling RC, et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation. 2001 ; 103 (18). 2254-2259.